Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-25-049868
Filing Date
2025-11-06
Accepted
2025-11-06 07:34:31
Documents
98
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q cbio-20250930.htm   iXBRL 10-Q 1413258
2 EX-10.1 crescent-2025inducementpla.htm EX-10.1 140074
3 EX-10.3 exhibit-103xwuxibioxdcmsax.htm EX-10.3 17007
4 EX-31.1 exhibit-311.htm EX-31.1 9377
5 EX-31.2 exhibit-312.htm EX-31.2 9703
6 EX-32.1 exhibit-321.htm EX-32.1 3619
7 EX-32.2 exhibit-322.htm EX-32.2 3516
  Complete submission text file 0001628280-25-049868.txt   8001844

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cbio-20250930.xsd EX-101.SCH 63180
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT cbio-20250930_cal.xml EX-101.CAL 52737
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT cbio-20250930_def.xml EX-101.DEF 427447
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cbio-20250930_lab.xml EX-101.LAB 692596
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cbio-20250930_pre.xml EX-101.PRE 609571
101 EXTRACTED XBRL INSTANCE DOCUMENT cbio-20250930_htm.xml XML 787198
Mailing Address 300 FIFTH AVENUE WALTHAM MA 02451
Business Address 300 FIFTH AVENUE WALTHAM MA 02451 617-430-5595
CRESCENT BIOPHARMA, INC. (Filer) CIK: 0001253689 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36177 | Film No.: 251456182
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)